Multiple endocrine neoplasia type 4

Multiple endocrine neoplasia type 4 is a rare sub-type of Multiple endocrine neoplasia.[1] The condition is commonly referred to as "MEN4".

According to the National Library of Medicine, "in MEN4, there is a mutation in the cyclin-dependent kinase inhibitor 1B gene (CDKN1B)."[1]

The clinical manifestations of MEN type 4 include hyperparathyroidism, pituitary adenomas, and tumors. [2]

While it was formerly called "MENX", the condition was renamed "MEN4" at the 11th International Workshop on MENs in Delphi, Greece. [3]

References

  1. ^ a b Ahmed, Fahad W.; Majeed, Muhammad S.; Kirresh, Omar (2025), "Multiple Endocrine Neoplasias Type 4", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 33760487, retrieved 2026-02-02
  2. ^ Frederiksen, Anja; Rossing, Maria; Hermann, Pernille; Ejersted, Charlotte; Thakker, Rajesh V.; Frost, Morten (2019-09-01). "Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases". The Journal of Clinical Endocrinology and Metabolism. 104 (9): 3637–3646. doi:10.1210/jc.2019-00082. ISSN 1945-7197. PMC 6637788. PMID 30990521.
  3. ^ Alevizaki, M.; Stratakis, C. A. (July 2009). "Multiple endocrine neoplasias: advances and challenges for the future". Journal of Internal Medicine. 266 (1): 1–4. doi:10.1111/j.1365-2796.2009.02108.x. ISSN 1365-2796. PMC 3138202. PMID 19522821.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.